Influence of Organic Anion Transporting Polypeptide1B1(OATP1B1) Genotype on Rosuvastatin PK, PD and Lipid Profiles — OATP

Rosuvastatin Clinical Trial

Official title:
Influence of OATP1B1 Genotype on the Pharmacokinetics,Lipid Lowering Effect, and Lipid Profiles After Rosuvastatin Administration

Status Completed

Clinical Trial Summary

This study aimed to explore the influence of organic anion transporting polypeptide1B1 (OATP1B1) genotype on pharmacokinetics, lipid lowering effect and lipid profiles after rosuvastatin administration.

Clinical Trial Description

Open, one arm, single sequence study for healthy volunteers are investigated. Thirty four subjects may be enrolled.

Rosuvastatin are administered once a day for 21 days. Before and after rosuvastatin administration, PK, PD and lipid profiles are investigated. ;

Study Design

Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Organic Anion Transporting Polypeptide1B1 (OATP1B1)
Rosuvastatin

Clinical Trial Details

NCT number	NCT01218347
Study type	Interventional
Source	Seoul National University Hospital
Contact
Status	Completed
Phase	Phase 4
Start date	October 2010
Completion date	December 2010

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00228514` - Dutch Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). PET Sub Study	Phase 3
	Withdrawn	`NCT03526367` - A Randomized Trial of Rosuvastatin Loading Combined With Early hydrAtion Versus Standard-of-care Medications for the Prevention of CIAKI in Patient With AMI Undergoing Emergency PCI	Phase 4